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Abstract
In breast cancer patients, hematogenous tumor cell dissemination
can be detected, even at the single cell level, by applying
immunocytochemical and molecular assays. Various methods for
the detection of circulating tumor cells in the peripheral blood have
been described. Results from recently reported studies suggest
that circulating tumor cell levels may serve as a prognostic marker
and for the early assessment of therapeutic response in patients
with metastatic breast cancer. However, in early-stage breast
cancer, the impact of circulating tumor cells is less well established
than the presence of disseminated tumor cells in bone marrow;
several clinical studies have demonstrated that cells of the latter
type are an independent prognostic factor at primary diagnosis. In
this article we briefly summarize recent studies examining the
presence of circulating tumor cells in the blood and discuss further
clinical applications.
Introduction
Adjuvant systemic therapy has contributed substantially to
the decline in mortality from breast cancer in the Western
world [1]. However, adjuvant systemic therapy is associated
with substantial cost and toxicity. With the use of traditional
prognostic factors, it is still not possible to reliably identify
those breast cancer patients who will relapse with metastatic
disease [2]. Research efforts have therefore been undertaken
to identify additional parameters enabling individual risk
assessment. In addition to their role as prognostic factors,
these parameters may also serve as targets for new
therapeutic approaches (for example HER-2/neu and
trastuzumab) [3].
Classically, prognostic factor research has been focused on
molecular characteristics of the primary tumor. However, it
seems more logical to examine micrometastases in distant
sites as an indication of future cancer behavior. In that regard,
immunocytochemical and molecular assays enable the
specific detection of systemically detected metastatic tumor
cells, even at the single-cell stage, in the blood and bone
marrow (BM). These technical advances provide an
opportunity to study one of the first crucial steps in the
metastatic cascade.
Because BM collection is invasive and inconvenient, many
investigators have studied techniques to detect and
characterize tumor cells in blood. Recently reported studies
indicate that, with modern detection techniques, circulating
tumor cells (CTCs) could provide a reliable and convenient
source for clinically relevant analysis. Pretreatment CTC levels
seem to be prognostic in women with metastatic disease
starting a new therapy. Moreover, CTC levels may also be
important in determining therapeutic efficacy. Fewer data are
available for CTCs in patients with early stage disease.
In this review we consider the current aspects in the field of
CTC detection in breast cancer patients and discuss
perspectives for clinical and research applications.
Techniques for detecting CTCs: new
developments for tumor cell enrichment and
cell detection
Enumeration of CTCs in human blood is fraught with many
challenges. First, one must separate these rare cancer cells
from billions of erythrocytes and millions of leucocytes
present in 10 ml of blood, and then one must confirm that the
identified ‘event’ is, indeed, a CTC. Many strategies have
been used to separate CTCs from normal blood cells (e.g.
centrifugal migration through Ficoll gradient or filtration), and
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to confirm the malignant origin of the cells on the basis of the
identification of epithelial or breast-specific markers.
For rigorous multicenter studies and/or routine clinical use, it
is of importance to demonstrate reproducibility of evaluations
and stability of blood samples, to allow shipment of samples.
With modern assay systems, such requirements can be
fulfilled [4]. In this regard, recent developments of new
enrichment systems for CTCs seem to provide an accurate
and reliable method to identify and characterize these rare
events [5,6]. For example, the nearly entirely automated
system, designated CellSearch™, has been cleared by the
US Federal Drug Administration. This system combines
immunomagnetic enrichment and fluorescent immunocyto-
chemical characterization of these rare events. In a
prospective, multi-institutional clinical trial, CTC detection
with this system provided significant prognostic information
both before and soon (4 weeks) after initiation of chemo-
therapy in patients with measurable metastatic breast cancer
[6,7]. A prospective randomized clinical trial is planned by the
US Breast Cancer Intergroup, led by the Southwest
Oncology Group, to evaluate whether patients with
metastatic breast cancer who have persistently elevated CTC
levels after one cycle of first-line chemotherapy benefit from
an early change of therapy.
PCR-based assays for CTC detection
Expression of epithelial and/or breast cancer-specific genes
can be exploited to provide evidence of disseminated tumor
cells (DTCs). In addition to immunologic techniques, PCR
techniques have been employed to detect these rare events.
The major limiting factor for the detection of single tumor
cells by RT-PCR is illegitimate low-level transcription of
tumor-associated or epithelium-specific genes in normal
cells [8]. Quantitative RT-PCR may increase discrimination
between mRNA expression in normal cells and tumor cells,
thereby increasing the specificity of the RT-PCR approach.
In one study, Ring and colleagues [9] compared immuno-
magnetic separation or cell filtration combined with laser
scanning cytometry with a multimarker real-time RT-PCR
assay for the detection of breast cancer cells. The
multimarker real-time RT-PCR assay was found to be the
most sensitive technique for the detection of CTCs [9].
However, it is not clear which of the methods provides
clinical relevant information.
Two separate studies have suggested that RT-PCR detection
of CTCs is associated with poor prognosis. One of these
employed cytokeratin 19 RT-PCR in the blood of non-
metastatic breast cancer patients before adjuvant therapy
[10], whereas in the other a multimarker PCR assay was used
to detect CTCs in metastatic patients [11]. CTC detection by
PCR for cytokeratin 19 before neoadjuvant chemotherapy
has also been reported to be associated with an increased
risk for recurrence [12]. These intriguing but preliminary
results require validation in prospective multicenter studies,
because assay conditions vary between studies and there is
no consensus regarding these conditions.
Can blood examination replace BM aspiration?
Results from individual studies, and a recently published
pooled analysis of several studies, have consistently
demonstrated that the presence of DTCs in BM has a strong
prognostic impact on patient survival [13]. Because BM
aspiration and biopsy are invasive and inconvenient, several
investigations have addressed whether one might garner the
same information from CTCs. Preliminary studies suggest
that CellSearch™ can be used to detect DTCs in BM and
CTCs in blood of patients with primary breast cancer [14,15].
Optimal cutoff values for different patient groups are still
under investigation. At the San Antonio Breast Cancer
Symposium in 2005, it was reported that prognostic
information from CTC determination can also be obtained in
patients treated with endocrine therapy but that the optimal
time point for the evaluation of CTCs in these patients might
be later during the course of treatment than for patients
treated with chemotherapy [16]. In addition, for certain
patient groups (for example, patients with estrogen receptor-
negative tumors or patients treated with chemotherapy) the
clinically relevant number of CTCs might be lower than the
five cells previously described [16].
Recent studies suggest that the frequency of CTCs in blood
seems to be lower than that of DTCs in BM. Conventional
Ficoll gradient centrifugation might therefore not provide
sufficient enrichment of malignant cells. This could explain the
lack of clinical relevance of CTC detection described in
earlier studies.
Other methods of detection of CTCs and DTCs have also
been compared [5,17,18]. Using immunocytochemistry,
Piegra and colleagues [18] showed a correlation between
the detection of CTCs in the blood and DTCs in BM of
patients with primary breast cancer at the time of surgery.
However, although they did detect an association between
the two, only the presence of DTCs in BM provided
significant prognostic information. In a study by Wiedswang
and colleagues [17], CTCs and DTCs from BM were
examined by immunocytochemistry from breast cancer
patients with a median time of 40 months after operation.
Both the presence of CTCs and that of DTCs in BM was
significantly associated with disease-free survival and breast
cancer-specific survival, and the presence of both CTCs and
DTCs resulted in an especially poor prognosis. However, this
study did not exclude patients who had relapsed before the
sampling of blood or BM. Excluding the patients with breast
cancer-related events before the sample collections, CTC
detection was not significantly associated with disease-free
survival/distant-disease-free survival, in contrast to DTC
detection [17]. Kataoka and colleagues [19] examined blood
and BM at the time of surgery for the presence of tumor cells
with a quantitative RT-PCR assay for cytokeratin 7 mRNA.Page 3 of 4
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The presence of CTCs in blood, but not DTCs in BM, was
correlated with an shorter distant metastasis-free survival. In
multivariate analysis, the presence of CTCs was an
independent prognostic factor in lymph-node-negative
patients [19]. This is in contrast to a study of Benoy and
colleagues [20], who found a prognostic impact only for BM
but not for blood with the use of RT-PCT for cytokeratin 19
and mammaglobin. This study also included patients with
metastatic breast cancer.
Currently, these findings do not support a change from DTC
detection from BM to CTC analysis. However, they do
suggest that the presence of CTCs could provide information
additional to that gained from DTC analysis.
Molecular characterization of CTCs
Recent technical developments permit an examination of the
genome of even single DTCs. Using immunocytochemistry,
immunofluorescence, and/or fluorescence in situ hybridization
(FISH), several groups have reported tumor-antigen expression
and/or chromosomal aberrations of DTCs in BM and CTCs,
indicating the malignant origin of these disseminated cells and
indicating genetic heterogeneity [2,21].
The biologic properties of CTCs are not yet well understood.
It seems that these cells have little proliferative potential [5].
With current techniques, it is also possible to perform gene
expression profiling from CTCs [22,23]. This enables studies
that should allow deeper insights into the mechanisms
allowing CTCs to form manifest metastasis. For example, it
seems that, for breast cancer, only a small proportion of
tumor cells, so-called ‘cancer stem cells’, have the capacity
for self-renewal and unlimited growth [24]. In view of the
resistance of DTCs and CTCs to chemotherapy it is possible
that some of these cells have stem-cell properties. Identifying
these ‘metastatic stem cells’ will be the one of the challenges
for future research.
One aspect of clinical importance is the identification of
therapeutic targets such as HER-2/neu on CTCs. HER-2 can
be detected on CTCs with cytogenetic [21], immunocyto-
chemical [25,26] and PCR methods [27]. There are several
possible implications of these findings. For example, it has
been reported that nearly one-third of patients whose primary
tumors were reportedly negative for HER-2 had CTCs with
amplified HER-2 (as determined by FISH). Given the
extraordinary impact of trastuzumab (Herceptin), a humanized
monoclonal antibody directed against HER-2, in both the
metastatic and adjuvant settings, monitoring CTCs for HER-2
could have an enormous influence on the application of this
therapy. In addition, the presence of HER-2-positive CTCs
seems to be associated with an impaired prognosis [26,27].
Conclusions and perspectives
Besides the prognostic information gained from CTCs, they
may also provide a tool for predicting or monitoring the
efficacy of systemic therapy. The study with the highest level
of evidence performed so far has been in patients with
metastatic disease. However, CTC measurements might also
have particular clinical relevance in the context of adjuvant
systemic therapy. Indeed, adjuvant therapeutic efficacy can
currently be assessed only in large-scale clinical trials after
observation periods of several years. An assay that permits
the assessment of treatment effects in this context is of high
clinical importance. It was previously shown that CTCs can
be detected during and after adjuvant or neoadjuvant
chemotherapy [5,28], but the clinical impact of this finding is
still unclear.
Prospective clinical studies are now ongoing to evaluate
whether the eradication of CTCs in the blood (and also DTCs
in BM) is correlated with a longer disease-free period and
overall survival in the adjuvant setting and whether therapy
guided by CTC testing is able to improve the outcome for
metastatic patients. An additional important goal is the
possibility of identifying metastatic-tumor-specific targets so
as to improve therapy regimens.
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